Why the study?
Therapeutic options for severe neonatal CNS viral infections remain highly limited, partly due to a lack of epidemiological data to inform clinical trials.
This review highlights the clinical burden, epidemiology, and pipeline therapeutics for severe neonatal CNS viral infections, emphasizing the need for epidemiological data to inform future trials.
Rising neonatal CNS viral infections warrant clinical vigilance; leaves open optimal therapeutic strategies.
Congenital CMV, enteroviruses, human parechovirus and herpes simplex virus are all common causes of severe central nervous system (CNS) infection in neonates. The introduction of screening (i.e. newborn hearing screening programme), integration of molecular syndromic testing (i.e. multiplex polymerase chain reaction assays) and increase in sexually transmitted infections (i.e. anogenital herpes) have contributed to increases in each of these infections over the last decade. However, therapeutic options are highly limited in part due to the lack of epidemiological data informing trials. This review will describe our current understanding of the clinical burden and epidemiology of these severe neonatal CNS infections, outline the novel antiviral and vaccines in the pipeline and suggest future research studies which could help develop new therapeutics.
No takes yet. Share an insight, caveat, or question.
Abeywickrema et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: